Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancer

Anticancer Res. 2003 Sep-Oct;23(5b):4229-32.

Abstract

We report two cases with small cell lung cancer (SCLC) receiving multicyclic dose-intensified chemotherapy (DI-CT) supported by autologous blood progenitor cell transplantation (ABPCT). Both cases were initially treated with cisplatin (CDDP), etoposide (ETP) and concurrent thoracic irradiation, however they had recurrent disease within a year. After receiving conventional chemotherapy, they underwent multicyclic DI-CT consisting of CDDP, ETP and ifosfamide supported by G-CSF and ABPCT. Definite regression of the tumors was observed. Severe neutropenia and thrombocytopenia were encountered but they were reversible and no life-threatening complications were experienced. These results suggest the feasibility and effectiveness of multicyclic DI-CT and the usefulness of ABPCT as a treatment option for relapsed SCLC.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Ifosfamide / administration & dosage
  • Ifosfamide / adverse effects
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged

Substances

  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Cisplatin
  • Ifosfamide